Technology Platforms
At Creative Biolabs, we offer comprehensive oncolytic virus development services powered by our cutting-edge technology platforms. Our advanced platforms enable the engineering, construction, validation, and manufacturing of customized oncolytic viruses for cancer treatment research and development.
OncoVirapy™ Platform
Our flagship OncoVirapy™ platform integrates technologies from viral biology, immunology, and genetic engineering to provide comprehensive services for developing engineered oncolytic viruses. Built upon years of research in immunotherapy and oncology, this platform enables us to design viruses that take advantage of tumor-specific mutations, allowing preferential replication in target cancer cells. The OncoVirapy™ platform supports complete development workflows including detailed virus engineering with considerations for tropism and tumor-specific promoters, comprehensive in vitro and in vivo validation studies to assess therapeutic efficacy, and GMP-certified manufacturing processes for clinical-grade virus production.
Reverse Genetics Technology
Our reverse genetics technology platform revolutionizes the development of oncolytic viruses by enabling manipulation of viral genomes at the DNA/cDNA level. Unlike forward genetics, this approach starts with genetic modifications and analyzes the resulting phenotypic effects, making it particularly valuable for RNA virus optimization. Through directed deletions, insertions, point mutations, and gene knockdowns, we can enhance onco-selectivity, safety, toxicity, and stimulation of tumor-specific immunity. Our state-of-the-art plasmid-based reverse genetics system generates infectious viruses with replication kinetics similar to wild-type viruses while incorporating therapeutic enhancements such as tumor-killing factors, cytokines, or chemokines for improved clinical outcomes.
Bacterial Artificial Chromosome (BAC) Technology
Our BAC technology platform offers a sophisticated solution for manipulating large viral genomes, particularly beneficial for complex DNA viruses like herpes simplex virus, vaccinia virus, and baculoviruses. This approach allows us to stably maintain and propagate large genomic fragments (up to 300kb) in Escherichia coli, providing significant advantages over traditional cloning methods. The BAC platform enables precise genetic engineering with high fidelity over multiple generations, more accurate endogenous gene expression, and compatibility with numerous mammalian cell lines. Through a streamlined five-step process, we can quickly create recombinant viruses bearing therapeutic or reporter genes while maintaining the integrity of complex viral genomes.